Literature DB >> 24535375

The impact of wild-type reversion on transmitted resistance surveillance.

David C Boettiger1, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph, Matthew G Law.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24535375      PMCID： PMC4135036          DOI： 10.3851/IMP2746

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


× No keyword cloud information.
  15 in total

1.  Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.

Authors:  Karin J Metzner; Pia Rauch; Patrick Braun; Heribert Knechten; Robert Ehret; Klaus Korn; Rolf Kaiser; Nadine Sichtig; Britta Ranneberg; Jan van Lunzen; Hauke Walter
Journal:  J Clin Virol       Date:  2010-11-04       Impact factor: 3.168

Review 2.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

3.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 4.  HIV-1 genetic variation and drug resistance development.

Authors:  Sarah Megens; Kristel Van Laethem
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11       Impact factor: 5.091

5.  Use of laboratory tests and clinical symptoms for identification of primary HIV infection.

Authors:  Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn
Journal:  AIDS       Date:  2002-05-24       Impact factor: 4.177

6.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

7.  In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Authors:  Roger Paredes; Manish Sagar; Vincent C Marconi; Rebecca Hoh; Jeffrey N Martin; Neil T Parkin; Christos J Petropoulos; Steven G Deeks; Daniel R Kuritzkes
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

8.  Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients.

Authors:  Sasisopin Kiertiburanakul; Romanee Chaiwarith; Sunee Sirivichayakul; Rossana Ditangco; Awachana Jiamsakul; Patrick C K Li; Pacharee Kantipong; Christopher Lee; Winai Ratanasuwan; Adeeba Kamarulzaman; Annette H Sohn; Somnuek Sungkanuparph
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

9.  Persistence of HIV-1 transmitted drug resistance mutations.

Authors:  Hannah Castro; Deenan Pillay; Patricia Cane; David Asboe; Valentina Cambiano; Andrew Phillips; David T Dunn
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

10.  Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Authors:  Raph L Hamers; Rebecca Oyomopito; Cissy Kityo; Praphan Phanuphak; Margaret Siwale; Somnuek Sungkanuparph; Francesca Conradie; Nagalingeswaran Kumarasamy; Mariette E Botes; Thira Sirisanthana; Saade Abdallah; Patrick C K Li; Nicoletta Ngorima; Pacharee Kantipong; Akin Osibogun; Christopher K C Lee; Wendy S Stevens; Adeeba Kamarulzaman; Inge Derdelinckx; Yi-Ming Arthur Chen; Rob Schuurman; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  Int J Epidemiol       Date:  2010-11-10       Impact factor: 7.196
View more
  3 in total

1.  Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S.

Authors:  Awachana Jiamsakul; Sunee Sirivichayakul; Rossana Ditangco; Ka-Hing Wong; Patrick Ck Li; Jutarat Praparattanapan; Praphan Phanuphak; Edelwisa Segubre-Mercado; Wing-Cheong Yam; Thira Sirisanthana; Thida Singtoroj; Matthew Law
Journal:  AIDS Res Ther       Date:  2015-02-13       Impact factor: 2.250

2.  Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County.

Authors:  William Chan; Wilson Ly
Journal:  Heliyon       Date:  2019-09-11

3.  Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.

Authors:  Sam Miti; Ray Handema; Lloyd Mulenga; Jonathan K Mwansa; Elizabeth Abrams; Christiana Frimpong; Virginia M Burke; Mangani Zulu; Mpanji Siwingwa; David Mwakazanga; Sam Kalibala; Julie A Denison
Journal:  PLoS One       Date:  2020-08-17       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.